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Objectives: Within health economic models of metastatic cancer therapies assump-
tions on the relationship between progression-free survival (PFS) / time-to-progres-
sion (TTP) and overall survival (OS) are typically required; notably when OS data are 
immature or unavailable. A review was undertaken to identify the methods that have 
been used within health economic models regarding this relationship and to identify 
the rationale given for the approach taken, specifically in those situations where OS 
data were not available or immature. MethOds: All NICE technology appraisals in 
the advanced and/or metastatic cancer setting completed by December 2013 were 
reviewed. The review included all relevant appraisal documents publicly available on 
the NICE website containing information on the methods used and/or rationale for 
the approach taken to model the relationship between OS and PFS/TPP within the 
health economic model. This included the sponsor submission and updated analyses, 
the independent Assessment Report, and other reports/analyses in relation to the 
appraisal process. Results: In those instances where OS data were immature or not 
available, PFS/TTP was typically assumed to be a valid surrogate of OS. Justification 
for this assumption was inconsistently reported. In some health economic models 
a quantification of the assumed relationship was informed by published evidence 
and/or expert judgement. In some cases attempts were made to explore the potential 
impact of this relationship in sensitivity analysis. cOnclusiOns: The methods and/
or rationale given for the approach used to model the relationship between OS and 
PFS/TTP in health economic models has been inconsistently reported and justified. 
Whilst some health economic models attempted to quantify this relationship, further 
transparency is required. A consensus needs to emerge on the most appropriate 
approaches to be used within health economic models to quantify this relationship, 
specifically when OS data are not available or immature and to identify the circum-
stances when particular approaches may be most relevant.
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Objectives: Patient-level utility values for different stages of MBC and toxicities 
commonly associated with chemotherapy regimens are useful for health economic 
assessments. Three methods to estimate utilities exist when direct utility data are 
not available: utility ‘mapping’ from existing disease-specific scales, vignette studies 
that describe the health states; or derivation of preference-based measures from 
an existing condition-specific scale. This study compares utility estimates in MBC 
utilizing the above methods. MethOds: Based on data from a phase 3 clinical 
trial in MBC (N= 1102) utility mapping was conducted using a published regression 
algorithm to convert the EORTC QLQ-C30 questionnaire to the EQ-5D utility. Mean 
utility values were estimated for relevant health states: stable disease (SD), tumor 
response (TR), disease progression (DP) and common toxicities. Results were com-
pared to previously published values obtained for a vignette study conducted in 
one hundred members of the general public. Results: Observed MBC utilities were 
similar in mapping vs. vignette studies for SD: 0.697 vs. 0.715, and TR: 0.782 vs. 0.790. 
General public respondents in the vignette study assigned much lower utility to 
symptomatic DP (0.443) vs. imaging-based DP in mapping study (0.679); and disutil-
ity for toxicities: vomiting: 0.103 vs. 0.050; fatigue 0.115 vs. 0.029; febrile neutropenia 
0.150 vs. 0.012 (vignette vs. mapping respectively). Hand-foot syndrome, stomatitis 
and hair loss were not associated with disutility in the mapping study (potentially 
due to small sample size) while disutility of 0.116; 0.151; and 0.114 were reported 
by the vignette study. cOnclusiOns: Utilization of different methods to estimate 
utilities in MBC may lead to a wide range of estimated values with potentially sig-
nificant implications for health economic evaluation. Caution must be exercised 
when comparing utility values derived using different methods. It is preferable to 
collect such data from patients directly and use vignettes as a last resort.
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Objectives: To compare different COPD cost-effectiveness models with respect 
to structure and input parameters and to cross validate the models by running 
the same hypothetical treatment scenarios. MethOds: COPD modeling groups 
simulated four hypothetical interventions with their model and compared the 
results with a reference scenario of no intervention. The four interventions mod-
eled assumed: 1) 20% reduction in decline in lung function, 2) 25% reduction in 
exacerbation frequency, 3) 10% reduction in all-cause mortality and 4) all these 
effects combined. The interventions were simulated for a five-year and lifetime 
horizon with standardization, if possible, for sex, age, COPD severity, smoking status, 
exacerbation frequencies, mortality due to other causes, utilities, costs and dis-
count rates. Furthermore, uncertainty around the outcomes of intervention four was 
compared. Results: Seven out of nine contacted COPD modeling groups agreed to 
participate. Differences in 5-year QALY gains ranged from 0.00020 to 0.039 for inter-
vention one, 0.0089 to 0.075 for intervention two and 0.017 to 0.048 for intervention 
three. The difference in costs ranged from € 561 to € 912 for intervention one, € 739 
to € 1350 for intervention two and € 1140 to € 1618 for intervention three. The 5-year 
cost-effectiveness ratios (ICERs) for the most comprehensive intervention, interven-
tion four, was € 17,000/QALY for two models, € 25,000-€ 28,000/QALY for three models 
addition, the Dutch National Health Care Institute commented on usefulness for 
decision makers, while a separate group of 50 HE experts could comment during a 
workshop at ISPOR Montreal 2014. Results: 35 Validation techniques were identi-
fied and grouped into four categories: conceptual model validation, computerized 
model validation, data validation and operational validation. Around 30 HE experts 
commented in each of the first three Delphi rounds, resulting in a 15 item draft 
tool. The Dutch health care advisory institute suggested to add one more item. 
Participants from the ISPOR workshop delivered 19 filled-in questionnaires. A fourth 
round resulted in 17 responses. This led to a refined version containing 16 items, 
which is currently sent out for a final, fifth round. cOnclusiOns: When filled 
out by the modellers, AdVISHE (Assessment of the ValIdation Status of Health-
Economic decision models) supports model users in assessing the validation status 
of a model It will be useful as part of reimbursement dossiers, by providing system-
atic and transparent insight into the validation efforts performed and their results.
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Objectives: Traditional indirect treatment comparison methods assume the 
underlying survival profiles of treatments are similar (i.e. proportional hazards). This 
assumption is unlikely to hold for the comparison of ipilimumab and vemurafenib: 
Whereas vemurafenib exhibits improved short-term survival compared with ipili-
mumab, pooled study data for ipilimumab consistently show that patients achieve 
durable long-term survival. We present a method to compare across trials with dif-
fering survival profiles by accounting for follow-on treatments and different patient 
baseline characteristics. MethOds: Comparative survival estimates for ipilimumab 
and vemurafenib were produced using patient-level data from trial CA184-024 for 
ipilimumab and published survival curve fits from BRIM-3 (along with registry data) 
for vemurafenib. The BRIM-3 vemurafenib overall survival curve was adjusted to 
account for (a) the effect of second-line ipilimumab (via a tunnel-state methodol-
ogy) and (b) differences in patient baseline characteristics between BRIM-3 and 
CA184-024, by means of a model (Korn model), constructed to predict the outcomes 
for dacarbazine-treated patients. The resulting survival estimates were compared 
with naïve unadjusted survival curve fits, and estimates produced using a hazard 
ratio (from an indirect comparison) to the ipilimumab data. Results: Estimated 
survival for ipilimumab was 3.3 years (mean). Predicted survival for vemurafenib, 
using a naïve comparison, was 3.0 years (mean). Adjusting for second-line ipili-
mumab and different baseline characteristics resulted in an estimate of 2.8 years 
for vemurafenib. When a hazard ratio was applied to the ipilimumab data, which 
underlies the here strong assumption that the vemurafenib overall survival profile 
is similar to that of ipilimumab, predicted survival for vemurafenib increased to 4.2 
years.cOnclusiOns: Depending on the methodology used, the mean predicted 
survival for vemurafenib varied from 2.8 to 4.2 years. Alternative methods that 
incorporate the long-term survival profile of ipilimumab (naïve comparison or more 
sophisticated adjustment methodology) demonstrate a higher number of life years 
with ipilimumab versus vemurafenib. 
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Objectives: Alzheimer’s Disease destroys brain cells, causing problems with mem-
ory, thinking, and behavior severe enough to affect work, family and social relation-
ships, and, eventually, the most basic activities of daily living. Different treatment 
options have been introduced and evaluated from a health economic perspective. 
However, given the specific characteristics of the disease an evaluation of existing 
models is needed. MethOds: The following databases were searched systemati-
cally: PubMed, Health Technology Assessment Database, NHS Economic Evaluation 
Database, Cochrane Central Register of Controlled Trials, Cochrane Database of 
Systematic Reviews, DAHTA-database, PSYNDEX and PsycINFO. For the abstracts 
that met the pre-defined inclusion criteria, full text articles were obtained and 
evaluated for inclusion in the assessment. Results: After eliminating duplicates 
the search indicated yielded 1’219 articles of which another 940 were excluded based 
on the title selection. Finally 59 articles have been reviewed in full text after abstract 
review. Out of those articles 39 were deemed to be relevant based on the research 
question. The majority of models (48%) have been Markov models, other methods 
being used were various statistical analysis applications, micro-simulation, and 
discrete-event simulations. Limitations of existing models include the following: 
Focus on cognitive function as disease progression only; lack of inclusion of correla-
tion between disease progression and other factors (e.g. residential status); lack of 
complete structure of diagnosis and treatment of disease (e.g. including non-drug 
treatments). Based on the Drummond checklist for health economic models the 
quality of models proved generally to be high but the majority of those lack present-
ing a comprehensive pathway of the natural history of the disease. cOnclusiOns: 
Current models do not allow decision makers optimally characterizing the disease, 
to better assess the costs and benefits of a wide range of potential interventions. 
Potential new models need to take the disease characteristics and specifics more 
appropriate into account.
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scores were compared to corresponding 10 year ACM predictions from the CDM. 
Base case (BC) analyses applied UKPDS-68 risk equations (UK68-RE) for CV risk and 
mortality. Two sets of sensitivity analyses were conducted using UK68-RE for CV risk 
but mortality tracked individually per complication event (non combined mortality 
approach) (SA1) and UKPDS-82 risk equations (UK82-RE) applied for CV risk and 
mortality (SA2). Results: Across all age and co-morbidity states, CDM simulations 
demonstrated the closest match to CCI-scores in SA1 with an R2-statistic of 0.877. 
This compared to R2-statistics of 0.757, and 0.851 for BC and SA2, respectively. BC 
and SA2 analyses noteworthy underestimated ACM risk in analyses with increased 
co-morbitity level by 68% (BC) and 49% (SA2) vs. 17% (SA1) in (MI+S+HF) and 44% 
(BC) and 36% (SA2) vs. 3% (SA1) in (MI+S+HF+RF). cOnclusiOns: The CDM dem-
onstrated a closer match to CCI mortality scores (vs. outcome studies) with a trend 
to underestimate ACM. This trend increased with baseline age and (only BC and 
SA2) co-morbidity level.
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Objectives: Multivariate functions can be used to predict individual risk for car-
diovascular (CVD) events and also to estimate baseline risk in economic models. 
We present a comparison of deterministic versus stochastic risk predictions using 
Framingham’s [D’Agostino 2008] and REACH’s [Wilson 2012] functions. Stochastic 
risk prediction accounts for patient-level heterogeneity, but involves a number of 
issues including increased complexity, data requirements, need for assumptions 
and computational burden. To our knowledge, this topic has not been studied in the 
CVD setting. MethOds: D’Agostino 2008 and Wilson 2012 modeled primary (PE) and 
recurrent event (RE) risks, respectively. Both studies considered fatal and non-fatal 
aggregate CVD events and estimated a Cox Proportional Hazards (CPH) multivariate 
risk function. In the deterministic prediction, the means of the risk factors were 
used to predict the population’s risk directly from the functions. In the stochastic 
prediction, individual patient profiles (n= 10,000) were generated using Monte Carlo 
simulation. Individual risks were then estimated from the functions and averaged 
to compute the population’s risk. Multinomomial distributions were assumed for 
discrete variables (e.g. diabetes, number of vascular beds) and normal or log-normal 
distributions were assumed for continuous variables depending on skewness (e.g. 
age, total cholesterol). Probability distributions were parameterized based on the risk 
factors descriptives reported in the original references. Simulations were performed 
with and without considering dependence of risk factors. Results: Due to the non-
linearity of the CPH function, the stochastic prediction yielded 23% (PE) and 17% 
(RE) higher risks than the deterministic approach (14% and 10%, respectively, if age 
was kept constant). Differences between prediction approaches are even higher if 
the estimated correlation structure of risk factors is accounted for. cOnclusiOns: 
When compared to the stochastic prediction, the deterministic approach leads to 
lower estimates of CVD risks. Therefore, economic models using this approach 
might underestimate treatment effect.
PRM89




Objectives: To present an alternative implementation for the conventional Markov 
models with area under the curve (AUC) approach: the continuous model (CM). 
To present how the CM avoids the need of determining cycles in theory and to 
compare the traditional and the CM approach in terms of results and complex-
ity in an oncology model example. MethOds: The AUC model assumes that the 
survival function is known at any timepoint not only at the beginning and end of 
model cycle. The CM calculates the model outcomes for the whole timehorizon by 
using the values of the survival function in every timepoint, instead of the discrete 
timepoints defined by cycle length. The CM approach overcomes the issue of the 
artificial characterization of time using cycles, that is often criticized in Markov 
models. Using CM can also lead to more precise estimates. A simple oncology AUC 
model with three health states (progression free survival, progression and death) 
and four-weekly cycles was built and converted to a CM model in Excel®, using 
user defined Visual Basic functions. Results, generalizability and user friendliness 
were compared. Results: The results of the two models were similar: for health 
outcomes differences were around 1%, for costs and incremental cost-effectiveness 
ratios around 0.5%. Calculations were done in a single cell/outcome instead of a 
column of 100-200 cells depending on cycle length and time horizon, giving less 
scope for bugs and facilitating easier debugging. As a result the implementation of 
the CM model was faster and technical validation easier. cOnclusiOns: The CM 
approach requires more technical background from the developer; custom func-
tions have to be built even for point estimates. However, results of a CM, requires 
smaller spreadsheet space, and provides more transparency and easier debugging, 
while providing similar or potentially more precise estimates compared to the AUC 
model results.
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Objectives: Markov models are a currently popular means of estimating the cost-
effectiveness of interventions; however they are associated with certain limitations 
which may make them ill-suited to inform some health care decisions. Patient simu-
lation models offer an alternative methodology which may overcome some of these 
and € 47,000/QALY for the remaining two models. Differences in the outcomes could 
mainly be explained by differences in input values for disease progression, exacer-
bation-related mortality and all-cause mortality with high input values resulting 
in low ICERs and vice versa. Lifetime results were mainly influenced by the input 
values for mortality. The probability of intervention four to be cost-effective at a 
willingness-to-pay of € 50,000/QALY was 90-100% for five models and about 70% and 
50% for the other two models. cOnclusiOns: Mortality was the most important 
factor determining the differences in cost-effectiveness outcomes between models.
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Objectives: The risk of cardiovascular (CV) events in post myocardial infarction 
(MI) patients poses a significant burden on the UK health care system despite the 
current standard of care (SoC). The objective of this analysis was to develop a model 
to quantify the relationship between efficacy and outcomes of a new hypothetical 
drug given in addition to current SoC to reduce the risk of CV events in post-MI 
patients when compared to SoC. MethOds: A 6-state lifetime Markov model with 
a 1-year cycle length was developed from a UK health care perspective. Recurrent 
MI, stroke and CV death were modeled. The hypothetical drug was assigned efficacy 
values for its ability to reduce the incidence of CV events. The outcomes were meas-
ured in terms of QALYs and LYs. A linear regression model was fitted to estimate 
the expected outcome/patient based on relative risk reduction (RRR) in the inci-
dence of CV events. All outcomes were discounted at 3.5% annually. Results: The 
model structure addressed some of the limitations of previous economic models, 
namely increased risk due to stroke in MI patients and increased risk of subse-
quent events in the first year. For identical cohorts, the outcomes from the model 
compared well with other published studies. For a cohort of patients aged 40-years, 
the model predicted on an average, LYs of 17.6 and QALYs of 13.64. A hypothetical 
drug achieving a 5% RRR in CV events resulted in an incremental LYs of 0.28 and 
QALYs of 0.23. The increase in incremental QALYs and LYs per percentage point 
reduction in relative risk as compared to SoC was estimated to be 0.043 and 0.054 
respectively. cOnclusiOns: A de-novo economic model quantifies the relationship 
between the efficacy and outcomes of a hypothetical drug when compared to the 
SoC to reduce the risk of CV events in post-MI patients.
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Objectives: The goals of type 2 diabetes management are to control glycaemia and 
other micro- and macrovascular risk factors such as weight, blood pressure and lipids 
in order to prevent death and other complications due to the disease. The natural 
history of the disease makes it challenging to estimate the effects of treatments on 
these long term complications and mortality from standard clinical trials. Modelling 
is therefore a key bridging tool for predicting long term health outcomes from inter-
mediate endpoints. The objective of this analysis was to estimate the relative effects 
of canagliflozin 300mg and sitagliptin 100mg on mortality, micro- and macrovascular 
complications in T2DM patients in triple line as add on to metformin plus sulpho-
nylurea using the UKPDS Outcomes Model v1.3. MethOds: A probabilistic patient 
generator was developed which generated 10,000 patients with applied treatment 
effects based on data from head to head randomised clinical trials. Upon loss of 
glycaemic control (HbA1c ≥ 7%), patients were assumed to switch to insulin. 1% point 
reduction in HbA1c was applied on rescue. For model stability, patients were looped 
1,000 times (creating 10 million patients in each arm) with 100 bootstrap simulations. 
Outcomes were discounted 3.5% annually. Results: At the end of the 40 years simu-
lation, patients initiating canagliflozin 300mg had 49 more survivors and 16,918 fewer 
diabetes-related deaths. Micro- and macrovascular complications were estimated 
in fewer patients on canagliflozin 300mg than on sitagliptin 100mg (between 5,948 
fewer renal failures and 41,157 fewer myocardial infarctions). There were discernible 
relative risk reductions in all complications and diabetes-related death ranging from 
1.40% (heart failure) to 2.96% (amputation). cOnclusiOns: Results of the analysis 
using the UKPDS Outcomes Model v1.3 suggest that canagliflozin 300mg compared 
with sitagliptin 100mg as add on to metformin plus sulphonylurea reduces long-term 
diabetes-related mortality and complications.
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Objectives: All cause mortality (ACM) validations with the IMS CORE Diabetes 
Model (CDM) have demonstrated below average fit when compared to overall vali-
dation scores from 96 validation end points (EP) with a R2-statistic of 0.651 (vs. 
0.93 All-EP). Lack of fit was associated with a model overestimation of ACM when 
compared to contemporary outcome studies (ACCORD, ADVANCE, VADT). The objec-
tive of this investigation was to put these findings into perspective by compar-
ing the model to mortality risk predictions from the Charlson-Comorbidity-Index 
(CCI). MethOds: The CCI was applied to predict the 10 year mortality risk for diabe-
tes patients with age of 50,60,70 and 80 years and four different co-morbidity levels: 
no complications (NC), myocardial infarction (MI), MI and stroke (MI+S), MI+S and 
heart failure (MI+S+HF) and MI+S+HF and renal failure (MI+S+HF+RF). CCI mortality 
